Scientists have long known that some cancers have preventable causes. But reliable estimates of how many, exactly, have been few and far between. New research provides the most comprehensive figures to date https://t.co/mWP4yeoe7m ...

Although there is cause for optimism, some types of cancer remain far less amenable to prevention than others https://t.co/mWP4yeoe7m ...

Reed Jobs was 12 when his father, Apple founder Steve Jobs, received a harrowing diagnosis: pancreatic cancer. He died eight years later at age 56.That tragedy led the younger Jobs to become an investor funding companies focused on preventing people from dying of cancer, which currently kills more than 600,000 a year in the United States alone.“We think it’s going to go from a death sentence to just a chronic lifelong disease,” Jobs told Forbes. “I think it’s doable in the timeframe of my lifetime for most ...

Reed Jobs was 12 when his father, Apple founder Steve Jobs, received a harrowing diagnosis: pancreatic cancer. He died eight years later at age 56.That tragedy led the younger Jobs to become an investor funding companies focused on preventing people from dying of cancer, which currently kills more than 600,000 a year in the United States alone.“We think it’s going to go from a death sentence to just a chronic lifelong disease,” Jobs told Forbes. “I think it’s doable in the timeframe of my lifetime for most ...

Business Performance - Lucid Diagnostics achieved a record quarterly revenue of $1.2 million in Q3 2024, a 20% increase compared to the previous quarter[6] - EsoGuard test volume reached 2,787 in Q3 2024[6] - Over 7,000 firefighters have undergone EsoGuard esophageal precancer testing[6] - Year-to-date revenue for 3Q24 reached $3.149 million, a $1.761 million increase compared to $1.388 million in 3Q23[34] Strategic Accomplishments - The ESOGUARD BE-1 clinical validation study was accepted for peer-reviewed publication[8] - A key patent underlying EsoGuard received a Notice of Allowance[8] - Lucid Diagnostics met with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's Molecular Diagnostics Program (MolDX) to discuss EsoGuard clinical evidence package for upcoming submission for Medicare coverage[8] Financials - Cash reserves decreased from $24.920 million in 2Q24 to $14.489 million in 3Q24, a decrease of $10.431 million[32] - Net loss for 3Q24 was $(12.371) million, compared to $(14.208) million in 3Q23, an improvement of $1.837 million[34] - Non-GAAP adjusted loss per share improved from $(0.22) in 3Q23 to $(0.20) in 3Q24[34] - Shares outstanding increased from 49.3 million in 2Q24 to 51.6 million in 3Q24, an increase of 2.3 million shares[32]

You know what I love about kids. I love how honest they are. I was working at a school-based health clinic the other day and I asked one of the kids, "What's your favorite subject?" Without missing a beat, he replied, "Lunch." And he's not alone.Did you know that 93% of Americans love to eat. But in all seriousness, here's the thing. That moment made me think about food, health, and nutrition in a way that I hadn't in a while.You see, 12 years ago, I was a pathology resident. A pathologist is a doctor that ...

Nutrition & Health Concerns - 93% of Americans love to eat, highlighting the widespread interest in food [1] - The increasing number of tumor cases in young people, especially young women and mothers, raises concerns about preventable diseases [3] - Nutrition is identified as a missing link in healthcare, impacting overall health [4] Familiarity & Education - People tend to stick to familiar food choices, making it more than just an access issue [6] - Children often choose chips or candy bars over fresh fruits and vegetables due to familiarity [6] - Nutrition education should be prioritized and instilled through repetition, similar to how the alphabet is taught [8] - It takes 8 to 15 exposures to a new food before a child accepts it [10] Solutions & Recommendations - Schools should offer kid-approved whole foods in lunches [11] - Countries like Japan teach nutrition, food preparation, and enjoyment, building lifelong healthy habits [12] - Families should prioritize fruits and vegetables at home to encourage nutritious snacking [13] - Small steps, like cooking together and honest conversations about food, can promote healthy eating habits [16]

Core Insights - Lucid Diagnostics Inc. has appointed Danielle Scelfo as Senior Vice President of Market Access & Government Affairs to enhance market access infrastructure and accelerate commercial coverage expansion for its EsoGuard Esophageal DNA Test [1][2] - The company is at a critical juncture, aiming to expand patient access to the EsoGuard test, with Medicare coverage anticipated following a positive MolDX CAC meeting [2][3] Company Overview - Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., focusing on patients with gastroesophageal reflux disease (GERD) who are at risk of esophageal precancer and cancer [3] - The EsoGuard test is the first and only commercially available tool designed for early detection of esophageal precancer in at-risk patients [3] Leadership and Experience - Danielle Scelfo brings over 25 years of experience in market access, reimbursement, and government affairs, having held senior roles in various diagnostics companies [2][3] - Her previous positions include Vice President at ClearNote Health and leadership roles at CareDx, Hologic, Adaptive Biotechnologies, and Genomic Health [2]

Summary of Lucid Diagnostics Conference Call Company Overview - **Company**: Lucid Diagnostics - **Founded**: 2018 - **Technology**: Focuses on detecting precancerous conditions for esophageal cancer, which is the second most deadly cancer [3][4] Industry Context - **Esophageal Cancer**: High mortality rate; early detection is crucial for prevention [4][5] - **Target Population**: Patients with heartburn and at least three out of six risk factors (e.g., over 50, white male, obese, smoker, family history) have about a 10% chance of having precancer [6] Core Technology and Testing Method - **Testing Method**: Non-invasive molecular test using a swallowable balloon capsule to collect samples from the lower esophagus [7][8] - **Performance Metrics**: - 99% negative predictive value [9] - 80% of patients can avoid invasive tests [10] - Approximately 40,000 tests performed to date [11] Financial and Coverage Insights - **Medicare Payment**: Established at $19.38 in 2021; ongoing efforts to secure coverage from Medicare and commercial payers [12] - **Current Testing Volume**: Approximately 2,756 tests in the latest quarter, a decrease from previous quarters due to waiting for coverage [14][15] - **Claim Denials**: About 83% of claims were denied in the quarter, primarily due to lack of medical policy coverage [20][21] Strategic Focus - **Coverage Strategy**: Engaging with payers to secure coverage; significant focus on building a clinical evidence package [12][19] - **Regional Plans**: Increased engagement with regional commercial plans, which are more willing to discuss coverage [24] - **Health System Partnerships**: Long-term partnerships with health systems to integrate testing into broader cancer prevention programs [25][26] Future Outlook - **Medicare Coverage Anticipation**: Expecting to secure Medicare coverage soon, which will allow for increased test volume and revenue growth [30][72] - **Market Opportunity**: Approximately 30 million patients recommended for screening, with 40-50% being Medicare age [30] - **Revenue Growth**: Anticipated solid revenue growth next year, with plans to ramp up operations post-Medicare approval [70][72] Competitive Landscape - **Comparison with Other Tests**: Lucid's test is positioned as more effective than sponge-based devices and blood tests for detecting precancerous conditions [82][88] - **Partnership Potential**: Opportunities for collaboration with other companies in the space to enhance market reach [81] Conclusion - **Growth Potential**: Lucid Diagnostics is poised for significant growth with the anticipated Medicare coverage and increasing commercial payer engagement, targeting a substantial market opportunity in esophageal cancer prevention [90][91]

Group 1 - Lucid Diagnostics Inc. announced a virtual public meeting on September 4, 2025, to discuss the reconsideration of Local Coverage Determination (LCD) L39256 for its EsoGuard® Esophageal DNA Test [1] - The meeting will involve Medicare Administrative Contractors and medical experts, focusing on the clinical literature related to esophageal precancer testing [2] - Lucid's CEO expressed optimism about the meeting's potential to lead to a positive Medicare coverage policy outcome, citing broad consensus in the GI community regarding the clinical utility of EsoGuard [2] Group 2 - Lucid Diagnostics is a commercial-stage company focused on cancer prevention, specifically targeting patients with gastroesophageal reflux disease (GERD) at risk of esophageal precancer [3] - The EsoGuard® Esophageal DNA Test is designed for early detection of esophageal precancer through a noninvasive procedure, representing a significant advancement in cancer prevention tools [3]